



Optime Care

Humatin Total Care Program

Provider Toolkit





Humatin™
(paromomycin sulfate) capsules



Contents:

Backgrounder	1
FAQ	2
Press Release: Optime Care Offers Patient-First Humatin Total Care Program, Maximizes Therapeutic Benefits of Humatin™ for Treatment of Intestinal Amebiasis	3
Schedule a Lunch & Learn	4
“Leave Behind” Document	6



Humatin Total Care Program

Humatin™ (paromomycin sulfate) for treating intestinal amebiasis is available exclusively through [Humatin Total Care](#).

Intestinal Amebiasis

- Intestinal amebiasis is a parasitic infection of the intestines caused by the protozoan *E. histolytica* that can affect anyone, although it is more common in people who live in or who have traveled to tropical areas with poor sanitary conditions.
- People become infected by ingesting contaminated food or water, or cysts (eggs) through contact with fecal matter of a person infected with the protozoan.
- Of those infected, approximately 10-20% become sick.
- Symptoms include loose stool, stomach pain and abdominal cramping, which usually develop within 2-4 weeks and are generally mild.

Prescribing Humatin

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Humatin and other antibacterial drugs, the Humatin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

To begin prescribing Humatin:

- Download, print and complete the [Humatin Total Care Enrollment Form and fax the completed form](#) to 833-488-1141, or
- Call Humatin Total Care at [1-844-486-2846, or](#)
- Use an [e-prescribing form](#)

Humatin Total Care

Optime Care's patient-first drug management program optimizes the benefits of Humatin for patients with acute and chronic intestinal amebiasis and as an adjunctive therapy for management of hepatic coma.

A dedicated Humatin Total Care coordinator works with insurance companies to verify coverage and reimbursement benefits, provide access to financial assistance and arrange drug delivery for the patient.



FAQ: Humatin Total Care Program

What is Humatin™ (paromomycin sulfate)?

This drug is used to treat intestinal amebiasis and available exclusively through [Humatin Total Care](#). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Humatin and other antibacterial drugs, the Humatin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

What is intestinal amebiasis?

Intestinal amebiasis is a parasitic infection of the intestines caused by the protozoan *E. histolytica*.

Who is at risk for contracting this infection?

Anyone can experience intestinal amebiasis, but it is more common in people who live in or who have traveled to tropical areas with poor sanitary conditions.

How do they become infected?

People become infected by ingesting contaminated food or water, or cysts (eggs) through contact with fecal matter of a person infected with the protozoan.

Of those infected, approximately 10-20% become sick.

What are the symptoms?

Symptoms include loose stool, stomach pain and abdominal cramping, which usually develop within 2-4 weeks and are generally mild.

How can I become a Humatin prescriber?

Providers can:

Download, print and complete the [Humatin Total Care Enrollment Form and fax the completed form](#) to 833-488-1141, or

Call Humatin Total Care at [1-844-486-2846](tel:1-844-486-2846), or

Use an [e-prescribing form](#)

What are the benefits of Humatin Total Care?

Optime Care's patient-first drug management program optimizes the benefits of Humatin for patients with acute and chronic intestinal amebiasis and as an adjunctive therapy for management of hepatic coma.

Our dedicated Humatin Total Care coordinator works with insurance companies to verify coverage and reimbursement benefits, provide access to financial assistance and arrange drug delivery for the patient.



Media:

Brittany Tedesco
CPR Communications
btedesco@cpronline.com
201.641.1911 x 14

Optime Care Offers Patient-First Humatin Total Care Program, Maximizes Therapeutic Benefits of Humatin™ for Treatment of Intestinal Amebiasis

Earth City, MO – July 6, 2021 – [Optime Care](#), a nationally recognized pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, announces the availability of Humatin™ (paromomycin sulfate) exclusively through [Humatin Total Care](#). This patient-first drug management program optimizes the benefits of Humatin for patients with acute and chronic intestinal amebiasis and as an adjunctive therapy for management of hepatic coma. Look for a provider toolkit available soon.

“Intestinal amebiasis is a parasitic infection of the intestines caused by a protozoan *Entamoeba histolytica* that can affect anyone, although it is more common in people who live in or who have traveled to tropical areas with poor sanitary conditions,” says Donovan Quill, president and CEO, Optime Care. “People become infected by ingesting contaminated food or water, or cysts (eggs) through contact with fecal matter of a person infected with the protozoan.”

Of those infected, approximately 10-20% become sick. Symptoms include loose stool, stomach pain and abdominal cramping, which usually develop within 2-4 weeks and are generally mild.

Optime Care’s patient-first approach can ensure care continuity across the entire patient journey with robust communication to yield rich data that clinicians can use to make more informed decisions and improve the overall patient experience.

Quill concludes, “Our dedicated Humatin Total Care coordinator works with insurance companies to verify coverage and reimbursement benefits, provide access to financial assistance and arrange drug delivery for the patient.”

To schedule a lunch and learn, contact Humatin Total Care Team at 1-844-486-2846.

About Optime Care

Optime Care, Inc. is a nationally recognized pharmacy, distribution and patient management organization offering a suite of comprehensive services tailored to maximize the therapeutic opportunities for the treatment of orphan and rare disorders. Our management team has previously partnered in the launch and management of more than 40 orphan products and programs and consistently implemented the best brand programs for the community. Our experience with small patient populations makes us uniquely qualified to help every stakeholder group impacted by these disorders. Optime Care has dual-accreditation from the Utilization Review Accreditation Commission (URAC) for compliance with specialty pharmacy and the Accreditation Commission for Health Care (ACHC) for specialty pharmacy services that demonstrate a commitment to providing quality care and services to consumers.

<https://www.optimecare.com/>





For more information, schedule a Lunch and Learn:

Contact Humatin Total Care Team

844-486-2846

Visit <https://humatintotalcare.com/>






Humatin™
(paromomycin sulfate) capsules

Humatin™ (paromomycin sulfate) is now available exclusively through Humatin Total Care.


To Enroll in Humatin Total Care:



Download Enrollment Form

Visit humatintotalcare.com to download the Humatin TotalCare Enrollment Form.

- or -



Call Humatin Total Care at 1-844-486-2846

If you need any further assistance with prescribing Humatin™ please contact Humatin Total Care at 1-844-486-2846.

For full prescribing information for Humatin™ please visit our website at humatintotalcare.com



Humatin™

(paromomycin sulfate) capsules

Indications and Usage

Paromomycin sulfate is indicated for intestinal amebiasis—acute and chronic (NOTE-It is not effective in extraintestinal amebiasis); management of hepatic coma—as adjunctive therapy.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Paromomycin Sulfate Capsules and other antibacterial drugs, Paromomycin Sulfate Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Dosage and Administration

Intestinal amebiasis: Adults and Pediatric Patients: Usual dose—25 to 35 mg/kg body weight daily, administered in three doses with meals, for five to ten days.

Management of hepatic coma:

Adults: Usual dose—4 g daily in divided doses, given at regular intervals for five to six days.

Precautions

Prescribing Paromomycin Sulfate Capsules in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

The use of this antibiotic, as with other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. Constant observation of the patient is essential. If new infections caused by nonsusceptible organisms appear during therapy, appropriate measures should be taken. The drug should be used with caution in individuals with ulcerative lesions of the bowel to avoid renal toxicity through inadvertent absorption.

Important Information for Patients

Patients should be counseled that antibacterial drugs including Paromomycin Sulfate Capsules should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Paromomycin Sulfate Capsules is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Paromomycin Sulfate Capsules or other antibacterial drugs in the future.

More information available at:

humatintotalcare.com